$ORIB
Orion Bliss Corp.

2024 Q2 Form 10-K Financial Statement

#000168316824003963 Filed on June 04, 2024

View on sec.gov

Income Statement

Concept 2024 Q2 2024 2023
Revenue $500.00 $600.00
YoY Change -16.67%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $52.86K $29.78K
YoY Change 77.48% 11.58%
Operating Profit -$52.36K -$29.18K
YoY Change 79.41%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income
YoY Change
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$52.36K -$29.18K
YoY Change 79.41% 9.34%
Net Earnings / Revenue -10471.2% -4863.67%
Basic Earnings Per Share $0.00 $0.00
Diluted Earnings Per Share $0.00 $0.00
COMMON SHARES
Basic Shares Outstanding 3.038M shares 3.038M shares 3.038M shares
Diluted Shares Outstanding 3.038M shares 3.038M shares

Balance Sheet

Concept 2024 Q2 2024 2023
SHORT-TERM ASSETS
Cash & Short-Term Investments
YoY Change
Cash & Equivalents $0.00
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $1.324K
YoY Change -83.27%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $1.324K
Total Long-Term Assets $0.00
Total Assets $1.324K
YoY Change
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable
YoY Change
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $90.52K
YoY Change 102.26%
LONG-TERM LIABILITIES
Long-Term Debt
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $90.52K
Total Long-Term Liabilities
Total Liabilities
YoY Change
SHAREHOLDERS EQUITY
Retained Earnings -$110.2K
YoY Change 90.59%
Common Stock $304.00
YoY Change 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$89.19K
YoY Change
Total Liabilities & Shareholders Equity $1.324K
YoY Change -83.27%

Cashflow Statement

Concept 2024 Q2 2024 2023
OPERATING ACTIVITIES
Net Income -$52.36K -$29.18K
YoY Change 79.41% 9.34%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$52.36K -$29.18K
YoY Change 79.41% 8.79%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $0.00
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $45.77K $36.96K
YoY Change 23.81% 37.8%
NET CHANGE
Cash From Operating Activities -$52.36K -$29.18K
Cash From Investing Activities
Cash From Financing Activities $45.77K $36.96K
Net Change In Cash -$6.591K $7.781K
YoY Change -184.71%
FREE CASH FLOW
Cash From Operating Activities -$52.36K -$29.18K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
CY2024 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2024 dei Entity Central Index Key
EntityCentralIndexKey
0001854183
CY2024 dei Document Type
DocumentType
10-K
CY2024 dei Document Annual Report
DocumentAnnualReport
true
CY2024 dei Document Period End Date
DocumentPeriodEndDate
2024-04-30
CY2024 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--04-30
CY2024 dei Document Transition Report
DocumentTransitionReport
false
CY2024 dei Entity File Number
EntityFileNumber
333-257326
CY2024 dei Entity Registrant Name
EntityRegistrantName
ORION BLISS CORP.
CY2024 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
CY2024 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
98-1591444
CY2024 dei Entity Address City Or Town
EntityAddressCityOrTown
Ashdod
CY2024 dei Entity Address Address Line1
EntityAddressAddressLine1
Kalonite 9-57
CY2024 dei Entity Address Country
EntityAddressCountry
IL
CY2024 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
7724233
CY2024 dei City Area Code
CityAreaCode
307
CY2024 dei Local Phone Number
LocalPhoneNumber
298 0969
CY2024 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2024 dei Entity Voluntary Filers
EntityVoluntaryFilers
Yes
CY2024 dei Document Fin Stmt Error Correction Flag
DocumentFinStmtErrorCorrectionFlag
false
CY2024 dei Entity Shell Company
EntityShellCompany
true
CY2023Q4 dei Entity Public Float
EntityPublicFloat
0 usd
CY2024Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
3038000 shares
CY2024 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2024 dei Auditor Name
AuditorName
Boladale Lawal
CY2024 dei Auditor Firm
AuditorFirmId
6993
CY2024 dei Auditor Location
AuditorLocation
Lagos, Nigeria
CY2024Q2 us-gaap Escrow Deposit
EscrowDeposit
1190 usd
CY2023Q2 us-gaap Escrow Deposit
EscrowDeposit
7781 usd
CY2024Q2 us-gaap Intangible Assets Current
IntangibleAssetsCurrent
134 usd
CY2023Q2 us-gaap Intangible Assets Current
IntangibleAssetsCurrent
134 usd
CY2024Q2 us-gaap Assets Current
AssetsCurrent
1324 usd
CY2023Q2 us-gaap Assets Current
AssetsCurrent
7915 usd
CY2024Q2 NONE Accounts Payable Related Party
AccountsPayableRelatedParty
37000 usd
CY2023Q2 NONE Accounts Payable Related Party
AccountsPayableRelatedParty
25000 usd
CY2024Q2 NONE Director Loan
DirectorLoan
53517 usd
CY2023Q2 NONE Director Loan
DirectorLoan
19752 usd
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
3038000 shares
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
3038000 shares
CY2024 us-gaap Operating Expenses
OperatingExpenses
52856 usd
CY2023 us-gaap Operating Expenses
OperatingExpenses
29782 usd
CY2024 us-gaap Net Income Loss
NetIncomeLoss
-52356 usd
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-29182 usd
CY2024 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
CY2024 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.00
CY2023 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
CY2023 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.00
CY2024 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3038000 shares
CY2024 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3038000 shares
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3038000 shares
CY2023 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3038000 shares
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
0 usd
CY2021Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
200 usd
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-1925 usd
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
-1725 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-26690 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-28415 usd
CY2023 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
20760 usd
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-29182 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-36837 usd
CY2024 us-gaap Net Income Loss
NetIncomeLoss
-52356 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-89193 usd
CY2024 us-gaap Net Income Loss
NetIncomeLoss
-52356 usd
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-29182 usd
CY2024 NONE Increase Decrease In Website Development
IncreaseDecreaseInWebsiteDevelopment
-0 usd
CY2023 NONE Increase Decrease In Website Development
IncreaseDecreaseInWebsiteDevelopment
-0 usd
CY2024 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-52356 usd
CY2023 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-29182 usd
CY2024 NONE Increase Decrease Accounts Payable Related Party
IncreaseDecreaseAccountsPayableRelatedParty
12000 usd
CY2023 NONE Increase Decrease Accounts Payable Related Party
IncreaseDecreaseAccountsPayableRelatedParty
12000 usd
CY2024 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
33765 usd
CY2023 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
4203 usd
CY2024 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 usd
CY2023 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
20760 usd
CY2024 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
45765 usd
CY2023 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
36963 usd
CY2024 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-6591 usd
CY2023 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
7781 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
7781 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
0 usd
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1190 usd
CY2024 us-gaap Interest Paid Net
InterestPaidNet
0 usd
CY2024 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0 usd
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-110153 usd
CY2024 us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_84E_eus-gaap--UseOfEstimates_zcOVOYrixJb2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Use of Estimates</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i> </i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date the financial statements and the reported amount of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
0 usd
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
0 usd
CY2023 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
0 shares
CY2024Q2 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
23132 usd
CY2024Q2 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
23132 usd
CY2024Q2 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0 usd
CY2024Q2 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
110153 usd
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000 shares
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
3038000 shares
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
3038000 shares
CY2024 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-10995 usd
CY2024 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
10995 usd
CY2024 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd

Files In Submission

Name View Source Status
0001683168-24-003963-index-headers.html Edgar Link pending
0001683168-24-003963-index.html Edgar Link pending
0001683168-24-003963.txt Edgar Link pending
0001683168-24-003963-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
image_001.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
none-20240430.xsd Edgar Link pending
orionbliss_ex3101.htm Edgar Link pending
orionbliss_ex3201.htm Edgar Link pending
orionbliss_ex9901.htm Edgar Link pending
orionbliss_i10k-043024.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
none-20240430_pre.xml Edgar Link unprocessable
orionbliss_i10k-043024_htm.xml Edgar Link completed
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
none-20240430_cal.xml Edgar Link unprocessable
none-20240430_def.xml Edgar Link unprocessable
none-20240430_lab.xml Edgar Link unprocessable